<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="Commonwealth University, [5], grid.224260.00000 0004 0458 8737Institute for Drug and" exact="Alcohol" post="Studies, Virginia Commonwealth University, epub: 2020-9-9pmc-release: 2020-9-9144received: 2020-2-26accepted: 2020-7-2(C)"/>
 <result pre="penetration of specific drugs. Keywords Antiretroviral therapy Astrocyte Blood-brain barrier" exact="Buprenorphine" post="C-C motif chemokine receptor 5 (CCR5) COVID-19 Cytochrome P450"/>
 <result pre="likelihood for abuse (Bell and Strang 2020), the use of" exact="buprenorphine" post="via telemedicine has become advantageous for managing OUD during"/>
 <result pre="CDC 2017). The second phase began in 2010 in which" exact="heroin" post="took the lead as the principal cause of overdose"/>
 <result pre="in 2013 in which highly potent synthetic opioids, such as" exact="fentanyl" post="and its analogs became the main cause of mortality"/>
 <result pre="mortality (Kolodyny et al. 2015; CDC 2017). The entry of" exact="fentanyl" post="and its analogs into the clandestine market has changed"/>
 <result pre="Laboratory Information System of the U.S. Drug Enforcement Administration (DEA)," exact="fentanyl" post="accounted for one-third of the illicit opioids seized in"/>
 <result pre="in proinflammatory cytokines and inflammatory mediators, including TNF-Î±, IL-1Î², and" exact="nitric oxide" post="synthase (NOS) (Dyuizen and Lamash 2009). Opiates especially drive"/>
 <result pre="(Hauser and Knapp 2014; McLane et al. 2018). For delayed" exact="heroin" post="overdose death after a survival period of 5Â h"/>
 <result pre="al. 2015) and cognitive impairment (Gruber et al. 2007). Moreover," exact="heroin" post="use is associated with symmetric T2 and fluid-attenuated inversion"/>
 <result pre="al. 2012, 2016; Hahn et al. 2016). Antagonizing CCR5 with" exact="maraviroc" post="reinstates morphine potency in an antinociceptive assay and restores"/>
 <result pre="encephalitis (HIVE) (Bell et al. 1998, 2002). In Indonesian injection" exact="heroin" post="abusers who lacked access to cART, CD4 counts (a"/>
 <result pre="of HIV progression) were reduced compared to PWH not using" exact="heroin" post="(Meijerink et al. 2014). However, with the introduction of"/>
 <result pre="plasma Human (Ryan et al. 2004) HIV ARV naive Reported" exact="heroin" post="use â€¢ â†&quot; MIP-1Î±, MIP-1Î², MCP-2 in blood after"/>
 <result pre="recall Human, female (Meyer et al. 2013) HIV cART Reported" exact="heroin" post="use â€¢ â†&quot; Recall memory â€¢ â†&quot; Working memory"/>
 <result pre="women, irrespective of HIV status â€¢ â†‘ Response time with" exact="cocaine" post="use Human (Martin et al. 2018) Visual and cognitive"/>
 <result pre="and Booth 2001) HIV cART OST â€¢ â†&quot; Frequency of" exact="heroin" post="injection â€¢ â†‘ On ARV Human (Pettes et al."/>
 <result pre="SUD C17T MOR polymorphism correlates with â†‘ risk of cocaine," exact="alcohol" post="&amp;amp; tobacco (but not opiate) use Human (Crystal et"/>
 <result pre="q.i.d., â‰¤ 4Â years) â€¢ â†‘ Survival time â€¢ â†‘" exact="Creatine" post="in white matter (SIVâ€‰+â€‰morphine only) â€¢ â†‘ Myo-inositol in"/>
 <result pre="tg, males (Fitting et al. 2016) Locomotor function Tat1â€&quot;86 No" exact="Oxycodone" post="(0â€&quot;10Â mg/kg, i.p., 15Â min prior behavioral assay) â†‘"/>
 <result pre="Motor skill Rhesus macaques (Marcario et al. 2016) Tat1â€&quot;86 No" exact="Oxycodone" post="(acute, 0.1â€&quot;10Â mg/kg, i.p.) â†‘ Psychomotor effects Mouse, Tat"/>
 <result pre="5Â days) â†&quot; Dolutegravir and abacavir, but no change in" exact="lamivudine" post="in brains of morphine-treated animals Mouse, Tat tg females"/>
 <result pre="CSF, cerebrospinal fluid; DAMGO [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DRD2L, type 2" exact="dopamine" post="receptor; DTG, dolutegravir; HIVE, HIV encephalitis (typically seen pre-cART);"/>
 <result pre="use disorder; tg, transgenic; t.i.d., three times a day; ZDV," exact="zidovudine" post="For practicality, Tables 1 and 2 are limited to"/>
 <result pre="al. 1995) HIVSF162 No â€¢ 8-CAC, U50,488 (KOR agonists) â€¢" exact="Cocaine" post="â€¢ KOR agonist â†&quot; p24; blocked by KOR antagonists"/>
 <result pre="tenofovir; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; ZDV," exact="zidovudine" post="For practicality, the table is limited to key studies"/>
 <result pre="in [Ca2+]i were not attenuated by ryanodine, whereas ryanodine and" exact="pyruvate" post="attenuate combined Tat and morphine-induced increases in [Ca2+]i. Nimodipine"/>
 <result pre="and pyruvate attenuate combined Tat and morphine-induced increases in [Ca2+]i." exact="Nimodipine" post="(L-type Ca2+ channel blocker) and dantrolene did not show"/>
 <result pre="exposure, morphine significantly reduced the levels of dolutegravir (f) and" exact="abacavir" post="(g), but not lamivudine (h), within the striatum, as"/>
 <result pre="the levels of dolutegravir (f) and abacavir (g), but not" exact="lamivudine" post="(h), within the striatum, as compared to placebo. (*"/>
 <result pre="(El-Hage et al. 2006b). Co-exposure of Tat and morphine or" exact="buprenorphine" post="to a BBB model increases monocyte transmigration in response"/>
 <result pre="the duration of opiate dependence (Ivers et al. 2018). Chronic" exact="oxycodone" post="exposure in rats causes some axonopathies and reduces the"/>
 <result pre="caspase-3 activation and TUNEL reactivity in OLs and reversible by" exact="naloxone" post="or naltrexone, respectively (Hauser et al. 2009). Although OLs"/>
 <result pre="immunoneutralizing antibodies (Hahn et al. 2012) or the selective antagonist," exact="maraviroc" post="(Balinang et al. 2017), were able to significantly attenuate"/>
 <result pre="et al. 2010). Similarly, the production of the inflammatory mediators" exact="prostaglandin E2" post="and the thromboxane A2 receptor by astrocytes is more"/>
 <result pre="MOR were noted when using a bivalent ligand derivative of" exact="maraviroc" post="linked to an opioid antagonist, naltrexone, with HIV-1 entry"/>
 <result pre="both astrocytes and microglia when morphine is present suggesting that" exact="maraviroc" post="therapy may not be effective with opiate co-exposure. Importantly,"/>
 <result pre="5 Differential inhibition of HIV-1 entry into human glia by" exact="maraviroc" post="and a bivalent CCR5-MOR antagonist (BVL) with cell-specific interactions"/>
 <result pre="morphine interactions (Kim et al. 2018). Similarly, short-duration (5 d)" exact="maraviroc" post="pre-treatment also eliminated neurotoxicity and attenuated neuronal increases in"/>
 <result pre="enhanced Tat-induced toxicity over a 72-h period (**pÂ pÂ c)." exact="Naloxone" post="or morphine by themselves had no effect on neuronal"/>
 <result pre="of Tat, restoring MSN survival to control levels. Pre-treatment with" exact="naloxone" post="re-established Tat toxicity, suggesting that the paradoxical protective effects"/>
 <result pre="stress-responsive hypothalamic-pituitary-adrenal (HPA) axis, the endogenous opioid system, and the" exact="dopamine" post="system (Kreek 1973; Kreek et al. 2002; George et"/>
 <result pre="Blendy 2008). Alternatively, chronic self-administration of short-acting opiates suppresses diurnal" exact="cortisol" post="rhythmicity (Facchinetti et al. 1984; Vuong et al. 2010),"/>
 <result pre="NAc shell demonstrates molecular and structural changes associated with intravenous" exact="heroin" post="self-administration (Jacobs et al. 2005). Moreover, earlier studies have"/>
 <result pre="including the NAc, frontal cortex, and striatum, and encompassed increased" exact="dopamine" post="and norepinephrine levels and turnover, which are central in"/>
 <result pre="NAc, frontal cortex, and striatum, and encompassed increased dopamine and" exact="norepinephrine" post="levels and turnover, which are central in opiate reward"/>
 <result pre="are central in opiate reward processes (Smith et al. 1982)." exact="Heroin" post="abuse is known to downregulate dopaminergic activity in the"/>
 <result pre="the NAc and may reflect a compensatory reduction in of" exact="dopamine" post="biosynthesis in response to excessive dopaminergic stimulation resulting from"/>
 <result pre="et al. 2001). Additionally, HIV is known to interfere with" exact="dopamine" post="neurotransmission (Nath et al. 2000b; Gaskill et al. 2017)"/>
 <result pre="al. 2000b; Gaskill et al. 2017) causing reductions in presynaptic" exact="dopamine" post="terminals and dopamine transport in the striatum (Wang et"/>
 <result pre="et al. 2017) causing reductions in presynaptic dopamine terminals and" exact="dopamine" post="transport in the striatum (Wang et al. 2004; Chang"/>
 <result pre="al. 2008; Midde et al. 2012, 2015). The decline in" exact="dopamine" post="function may exacerbate opioid abuse tendencies and drug-seeking behaviors"/>
 <result pre="of Selective/Biased Agonism in neuroHIV Pathogenesis Although morphine, methadone, and" exact="buprenorphine" post="all activate MOR, each can impart different signals through"/>
 <result pre="of KOR (Noble and Marie 2018). In comparison to methadone," exact="buprenorphine" post="has been shown to have fewer pharmacodynamic interactions with"/>
 <result pre="et al. 2010), and we found that morphine, methadone, and" exact="buprenorphine" post="differentially increase ROS and [Ca2+]i alone or following Tat"/>
 <result pre="metabolized primarily by cytochrome P450 (CYP) 3A4 and 2C8. Both" exact="buprenorphine" post="and its active metabolite, norbuprenorphine, are glucuronidated by UDP-glucuronosyltransferase"/>
 <result pre="UGT 1A1, leading to increases in overall systemic exposure of" exact="buprenorphine" post="and norbuprenorphine and also results in symptoms of opioid"/>
 <result pre="and impaired cognition (McCance-Katz et al. 2007). Dose adjustments of" exact="buprenorphine" post="are recommended when initiating therapy with atazanavir to avoid"/>
 <result pre="Dose adjustments of buprenorphine are recommended when initiating therapy with" exact="atazanavir" post="to avoid symptoms of opioid excess. Methadone is a"/>
 <result pre="(Bruce et al. 2006; Meemken et al. 2015). In contrast," exact="efavirenz" post="and nevirapine induce CYP 3A4, resulting in decreased systemic"/>
 <result pre="al. 2006; Meemken et al. 2015). In contrast, efavirenz and" exact="nevirapine" post="induce CYP 3A4, resulting in decreased systemic concentrations of"/>
 <result pre="avoid opioid withdrawal, increased methadone dosing is recommended when either" exact="efavirenz" post="or nevirapine therapy is initiated (Marzolini et al. 2000;"/>
 <result pre="withdrawal, increased methadone dosing is recommended when either efavirenz or" exact="nevirapine" post="therapy is initiated (Marzolini et al. 2000; Clarke et"/>
 <result pre="al. 2000; Clarke et al. 2001; Meemken et al. 2015)." exact="Oxycodone" post="metabolism is inhibited by lopinavir/ritonavir, increasing oxycodone concentrations as"/>
 <result pre="et al. 2015). Oxycodone metabolism is inhibited by lopinavir/ritonavir, increasing" exact="oxycodone" post="concentrations as well as the self-reported drug effects (Nieminen"/>
 <result pre="d continuous exposure to morphine on ARV brain concentrations (dolutegravir," exact="lamivudine" post="and abacavir) and demonstrated that morphine exposure resulted in"/>
 <result pre="2017). Another study measured intracellular concentrations of dolutegravir, tenofovir and" exact="emtricitabine" post="in primary human astrocytes, microglia, pericytes and BMECs (Patel"/>
 <result pre="improved ART adherence for HIV-infected women who use illicit drugsDrug" exact="Alcohol" post="Depend202020610767031711873 AdlerMWGellerEBRogersTJHendersonEEEisensteinTKOpioids, receptors, and immunityAdv Exp Med Biol199333513208237587 AlaeeAZarghamiMFarniaSKhademlooMKhoddadTComparison"/>
 <result pre="in human lymphocytesAIDS2011251126112821422985 BabaMOishiRSaekiKEnhancement of blood-brain barrier permeability to sodium" exact="fluorescein" post="by stimulation of mu opioid receptors in miceNaunyn Schmiedeberg's"/>
 <result pre="damage in the brain: potential role of the thiol antioxidant" exact="N-acetylcysteine" post="amide. Free Radic Biol Med 48:1388â€&quot;1398 Banerjee A, Strazza"/>
 <result pre="dependence and HIV-1 infection on pattern shift visual evoked potentialsDrug" exact="Alcohol" post="Depend1998501471559649966 Becker WC, Fiellin DA (2020) When epidemics collide:"/>
 <result pre="receptorsProc Natl Acad Sci U S A199390539153938390660 BruceRDMcCance-KatzEKharaschEDMoodyDEMorseGDPharmacokinetic interactions between" exact="buprenorphine" post="and antiretroviral medicationsClin Infect Dis200643Suppl 4S216S22317109308 BruehlSApkarianAVBallantyneJCBergerABorsookDChenWGFarrarJTHaythornthwaiteJAHornSDIadarolaMJInturrisiCELaoLMackeySMaoJSawczukAUhlGRWitterJWoolfCJZubietaJKLinYPersonalized medicine and"/>
 <result pre="immunodeficiency virus type 1 transgenic rat modelJ Virol2007818406841117553897 ChangLWangGJVolkowNDErnstTTelangFLoganJFowlerJSDecreased brain" exact="dopamine" post="transporters are related to cognitive deficits in HIV patients"/>
 <result pre="related to cognitive deficits in HIV patients with or without" exact="cocaine" post="abuseNeuroImage20084286987818579413 ChaoCCGekkerGShengWSHuSPortoghesePSPetersonPKEndogenous opioid peptides suppress cytokine-mediated upregulation of HIV-1"/>
 <result pre="effect of HIV-1 coat protein gp120 on corticotropin-releasing hormone and" exact="arginine vasopressin" post="in the rat hypothalamus: involvement of nitric oxideExp Neurol200016637638411085902"/>
 <result pre="of HIV-1 coat protein gp120 on corticotropin-releasing hormone and arginine" exact="vasopressin" post="in the rat hypothalamus: involvement of nitric oxideExp Neurol200016637638411085902"/>
 <result pre="use in African American womenAddict Biol20121718119121070507 Culpepper-MorganJAKreekMJHypothalamic-pituitary-adrenal axis hypersensitivity to" exact="naloxone" post="in opioid dependence: a case of naloxone-induced withdrawalMetab Clin"/>
 <result pre="in progression of HIV-1 infections to AIDSJ Neuroimmunol19988377879610676 DonahoeRMFalekAMaddenJJNicholsonJKBokosPGallegosKVeitREffects of" exact="cocaine" post="and other drugs of abuse on immune functionAdv Exp"/>
 <result pre="http://www.healthdata.org/gbd/gbd-2017-resources. FacchinettiFGrassoAPetragliaFParriniDVolpeAGenazzaniARImpaired circadian rhythmicity of beta-lipotrophin, beta-endorphin and ACTH in" exact="heroin" post="addictsActa Endocrinol19841051491556320568 FalekADonahoeRMMaddenJJShaferDAOpiates as immunosuppressive and genotoxic agentsDrugs of"/>
 <result pre="notch ligand and activation of notch signaling pathwayJ Neurosci201636113621137327807176 FanRSchrottLMArnoldTSnellingSRaoMGrahamDCorneliusAKorneevaNLChronic" exact="oxycodone" post="induces axonal degeneration in rat brainBMC Neurosci2018191529571287 FauciASRedfieldRRSigounasGWeahkeeMDGiroirBPEnding the"/>
 <result pre="KJ, Geiger JD, Jordan-Sciutto KL, Grinspan JB (2019) Protease inhibitors," exact="saquinavir" post="and darunavir, inhibit oligodendrocyte maturation: Implications for Lysosomal Stress."/>
 <result pre="Gamble-George J, Yano H, Khoshbouei H (2017) HIV, Tat and" exact="dopamine" post="transmission. Neurobiol Dis 105:51â€&quot;73 Gandhi N, Saiyed ZM, Napuri"/>
 <result pre="human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and" exact="cocaine" post="in blood-brain barrier dysfunction: Implications for HIV-1â€&quot;associated neurocognitive disorder."/>
 <result pre="Endocr Metab Disord20131410511223728720 GeorgeOLe MoalMKoobGFAllostasis and addiction: role of the" exact="dopamine" post="and corticotropin-releasing factor systemsPhysiol Behav2012106586422108506 GerettiAMHIV-1 subtypes: epidemiology and"/>
 <result pre="Neurol1994535215348083694 GrayFScaravilliFEverallIChretienFAnSBocheDAdle-BiassetteHWingertsmannLDurigonMHurtrelBChiodiFBellJLantosPNeuropathology of early HIV-1 infectionBrain Pathol199661158866743 GrayLRTachedjianGEllettAMRocheMJChengWJGuilleminGJBrewBJTurvilleSGWesselinghSLGorryPRChurchillMJThe NRTIs lamivudine," exact="stavudine" post="and zidovudine have reduced HIV-1 inhibitory activity in astrocytesPLoS"/>
 <result pre="of early HIV-1 infectionBrain Pathol199661158866743 GrayLRTachedjianGEllettAMRocheMJChengWJGuilleminGJBrewBJTurvilleSGWesselinghSLGorryPRChurchillMJThe NRTIs lamivudine, stavudine and" exact="zidovudine" post="have reduced HIV-1 inhibitory activity in astrocytesPLoS One20138e6219623614033 GrimmMCBen-BaruchATaubDDHowardOMResauJHWangJMAliHRichardsonRSnydermanROppenheimJJOpiates"/>
 <result pre="Biol20182330431227739172 JacobsEHSmitABde VriesTJSchoffelmeerANLong-term gene expression in the nucleus accumbens following" exact="heroin" post="administration is subregion-specific and depends on the nature of"/>
 <result pre="Morgello S (2013) HIV-related cognitive impairment shows bi-directional association with" exact="dopamine" post="receptor DRD1 and DRD2 polymorphisms in substance-dependent and substance-independent"/>
 <result pre="and substance-independent populations. J Neurovirol 19:495â€&quot;504 JankovicBDHorvatJDjordjijevicDRamahAFridmanVSpahicOBrain-associated autoimmune features in" exact="heroin" post="addicts: correlation to HIV infection and dementiaThe International journal"/>
 <result pre="cortex cultureArch Virol199413781997526826 KishSJKalasinskyKSDerkachPSchmunkGAGuttmanMAngLAdamsVFurukawaYHaycockJWStriatal dopaminergic and serotonergic markers in human" exact="heroin" post="usersNeuropsychopharmacology20012456156711282256 Knapp PE, Hauser KF (1996) Î¼-Opioid receptor activation"/>
 <result pre="for active efflux transportersDrug Metab Dispos20144298398924644297 KolodynyACourtwrightDTHwangCSKreinerPEadieJLClarkTWAlexanderGCThe prescription opioid and" exact="heroin" post="crisis: a public health approach to an epidemic of"/>
 <result pre="Drug Discov2002171072612209151 KreekMJBartGLillyCLaForgeKSNielsenDAPharmacogenetics and human molecular genetics of opiate and" exact="cocaine" post="addictions and their treatmentsPharmacol Rev20055712615734726 KringenMKChalabianlooFBernardJPBramnessJGMoldenEHoisethGCombined effect of CYP2B6"/>
 <result pre="clade dependent. J Neurosci 28:12190â€&quot;12198 LiWLiQZhuJQinYZhengYChangHZhangDWangHWangLWangYWangWWhite matter impairment in chronic" exact="heroin" post="dependence: a quantitative DTI studyBrain Res20131531586423895765 LiGHAndersonCJaegerLDoTMajorEONathACell-to-cell contact facilitates"/>
 <result pre="task performance in SIV-infected rhesus macaquesJ NeuroImmune Pharmacol20161134835727039332 MarinhoATMirandaJPCaixasUCharneiraCGoncalves-DiasCMarquesMMMonteiroECAntunesAMMPereiraSASingularities of" exact="nevirapine" post="metabolism: from sex-dependent differences to idiosyncratic toxicityDrug Metab Rev201951769030712401"/>
 <result pre="between opioids and antiretroviral agentsClin Infect Dis200541Suppl 1S89S9516265622 McCance-KatzEFMoodyDEMorseGDMaQDiFrancescoRFriedlandGPadePRaineyPMInteraction between" exact="buprenorphine" post="and atazanavir or atazanavir/ritonavirDrug Alcohol Depend20079126927817643869 McDermottDHBeecroftMJKleebergerCAAl-SharifFMOllierWEZimmermanPABoatinBALeitmanSFDetelsRHajeerAHMurphyPMChemokine RANTES promoter"/>
 <result pre="and antiretroviral agentsClin Infect Dis200541Suppl 1S89S9516265622 McCance-KatzEFMoodyDEMorseGDMaQDiFrancescoRFriedlandGPadePRaineyPMInteraction between buprenorphine and" exact="atazanavir" post="or atazanavir/ritonavirDrug Alcohol Depend20079126927817643869 McDermottDHBeecroftMJKleebergerCAAl-SharifFMOllierWEZimmermanPABoatinBALeitmanSFDetelsRHajeerAHMurphyPMChemokine RANTES promoter polymorphism affects"/>
 <result pre="Infect Dis200541Suppl 1S89S9516265622 McCance-KatzEFMoodyDEMorseGDMaQDiFrancescoRFriedlandGPadePRaineyPMInteraction between buprenorphine and atazanavir or atazanavir/ritonavirDrug" exact="Alcohol" post="Depend20079126927817643869 McDermottDHBeecroftMJKleebergerCAAl-SharifFMOllierWEZimmermanPABoatinBALeitmanSFDetelsRHajeerAHMurphyPMChemokine RANTES promoter polymorphism affects risk of both"/>
 <result pre="inhibition of sheep erythrocyte binding to T lymphocytes: reversal by" exact="naloxone" post="and cyclic nucleotidesNIDA Res Monogr1981341591656783926 McLaneVDCaoLWillisCLMorphine increases hippocampal viral"/>
 <result pre="NM, Gomez AM, Zhu J (2012) HIV-1 Tat protein decreases" exact="dopamine" post="transporter cell surface expression and vesicular monoamine transporter-2 function"/>
 <result pre="at tyrosine 88, lysine 92 and tyrosine 470 of human" exact="dopamine" post="transporter result in an attenuation of HIV-1 Tat-induced inhibition"/>
 <result pre="transporter result in an attenuation of HIV-1 Tat-induced inhibition of" exact="dopamine" post="transport. J NeuroImmune Pharmacol 10:122â€&quot;135 MirsattariSMPowerCNathAPrimary headaches with HIV"/>
 <result pre="sleep, and cancer-related fatigueMed Hypotheses200258778211863402 Morales OdiaYJinkaMZiaiWCSevere leukoencephalopathy following acute" exact="oxycodone" post="intoxicationNeurocrit Care201013939720440598 MorganMMChristieMJAnalysis of opioid efficacy, tolerance, addiction and"/>
 <result pre="drugsAIDS2017311181119028323752 MullerUJTruebnerKSchiltzKKuhnJMawrinCDobrowolnyHBernsteinHGBogertsBSteinerJPostmortem volumetric analysis of the nucleus accumbens in male" exact="heroin" post="addicts: implications for deep brain stimulationEur Arch Psychiatry Clin"/>
 <result pre="MullerUJSchiltzKMawrinCDobrowolnyHFrodlTBernsteinHGBogertsBTruebnerKSteinerJTotal hypothalamic volume is reduced in postmortem brains of male" exact="heroin" post="addictsEur Arch Psychiatry Clin Neurosci201826824324828534187 MullerUJMawrinCFrodlTDobrowolnyHBusseSBernsteinHGBogertsBTruebnerKSteinerJReduced volumes of the"/>
 <result pre="volumes of the external and internal globus pallidus in male" exact="heroin" post="addicts: a postmortem studyEur Arch Psychiatry Clin Neurosci201926931732430173319 MurphyABarbaroJMartinez-AguadoPChilundaVJaureguiberry-BravoMBermanJWThe"/>
 <result pre="drugs of abuse and HIV infectionNeuroAIDS19992112 NathAJonesMMaragosWBoozeRMactutusCBellJHauserKFMattsonMNeurotoxicity and dysfunction of" exact="dopamine" post="systems associated with AIDS dementiaPsychopharmacol200014222227 NathAAndersonCJonesMMaragosWBoozeRMactutusCBellJHauserKFMattsonMNeurotoxicity and dysfunction of"/>
 <result pre="NieminenTHHagelbergNMSaariTINeuvonenMNeuvonenPJLaineKOlkkolaKTOxycodone concentrations are greatly increased by the concomitant use of" exact="ritonavir" post="or lopinavir/ritonavirEur J Clin Pharmacol20106697798520697700 NobleFMarieNManagement of opioid addiction"/>
 <result pre="Cell Biochem200830816917517934700 PetersPJet al.HIV infection linked to injection use of" exact="oxymorphone" post="in Indiana, 2014-2015N Engl J Med201637522923927468059 PetersonPKSharpBMGekkerGPortoghesePSSannerudKBalfourHHJrMorphine promotes the"/>
 <result pre="NeuroImmune Pharmacol2012787789122101471 PolliJWJarrettJLStudenbergSDHumphreysJEDennisSWBrouwerKRWoolleyJLRole of P-glycoprotein on the CNS disposition of" exact="amprenavir" post="(141W94), an HIV protease inhibitorPharm Res1999161206121210468021 PriceRWBrewBSidtisJRosenblumMScheckACClearyPThe brain in"/>
 <result pre="HIV-1 infection and AIDS dementia complexScience19882395865923277272 ProtassLMDelayed postanoxic encephalopathy after" exact="heroin" post="useAnn Intern Med1971747387395559439 ProudnikovDRandesiMLevranOCrystalHDornMOttJHoAKreekMJAssociation of polymorphisms of the mu"/>
 <result pre="persistenceAIDS Rev201921112230899112 QiuYJiangGSuHLvXZhangXTianJZhuoFProgressive white matter microstructure damage in male chronic" exact="heroin" post="dependent individuals: a DTI and TBSS studyPLoS One20138e6321223650554 Qureshi"/>
 <result pre="Dis 49:780â€&quot;786 Salahuddin MF, Qrareya AN, Mahdi F, Jackson D," exact="Foster" post="M, Vujanovic T, Box JG, Paris JJ (2020) Combined"/>
 <result pre="T, Box JG, Paris JJ (2020) Combined HIV-1 Tat and" exact="oxycodone" post="activate the hypothalamic-pituitary-adrenal and -gonadal axes and promote psychomotor,"/>
 <result pre="Med 14:e8â€&quot;e9. 10.1097/ADM.0000000000000685 SanchezESBigbeeJWFobbsWRobinsonSESato-BigbeeCOpioid addiction and pregnancy: perinatal exposure to" exact="buprenorphine" post="affects myelination in the developing brainGlia2008561017102718381654 SarkisyanDHussainMZWatanabeHKononenkoOBazovIZhouXYamskovaOKrishtalOKarpyakVMYakovlevaTBakalkinGDownregulation of the"/>
 <result pre="Determination that a public health emergency exists. https://www.hhs.gov/sites/default/files/opioid%20PHE%20Declaration-no-sig.pdf SerafiniRAPryceKDZachariouVThe mesolimbic" exact="dopamine" post="system in chronic pain and associated affective comorbiditiesBiol Psychiatry202087647331806085"/>
 <result pre="turnover correlated with morphine-seeking behavior of ratsPharmacol Biochem Behav1982165095196123120 SmithJECoCLaneJDLimbic" exact="acetylcholine" post="turnover rates correlated with rat morphine-seeking behaviorsPharmacol Biochem Behav1984204294426538688"/>
 <result pre="Biol2003741074108212972507 SzetoCYTangNLLeeDTStadlinAAssociation between mu opioid receptor gene polymorphisms and Chinese" exact="heroin" post="addictsNeuroreport2001121103110611338173 TakahashiKYiHLiuCHLiuSKashiwagiYPatinDJHaoSSpinal bromodomain-containing protein 4 contributes to neuropathic pain"/>
 <result pre="attenuates the (âˆ’)-morphine-produced conditioned place preference and the mu-opioid receptor-mediated" exact="dopamine" post="increase in the posterior nucleus accumbens of the ratEur"/>
 <result pre="of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of" exact="heroin" post="craving. Biol Psychiatry 73:729â€&quot;737 ThompsonAROpioids and their proper use"/>
 <result pre="abuse. Cellular and molecular life sciences 64:2120â€&quot;2132 VenutoCSMollanKMaQDaarESSaxPEFischlMCollierACSmithKYTierneyCMorseGDSex differences in" exact="atazanavir" post="pharmacokinetics and associations with time to clinical events: AIDS"/>
 <result pre="opioid use disorder: a research synthesis and meta-analysisAm J Drug" exact="Alcohol" post="Abuse201945112530359116 Wu DT, Woodman SE, Weiss JM, McManus CM,"/>
 <result pre="spliced mu opioid receptor variants: mMOR-1A, mMOR-1O, and mMOR-1PSynapse20146814415224375714 XuJLuZXuMPanLDengYXieXLiuHDingSHurdYLPasternakGWKleinRJCartegniLZhouWPanYXA" exact="heroin" post="addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA"/>
</results>
